Ocular Therapeutix (OCUL) Finished Goods (2014 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Finished Goods of $2.4 million for Q2 2026, up 125.65% year-over-year from $1.1 million in Q2 2025, and up 10.78% on a QoQ basis from $2.2 million in Q1 2026.
Ocular Therapeutix (OCUL) Finished Goods (2014 - 2026) Analysis & Trends
Ocular Therapeutix has reported Finished Goods for 13 years, with the latest figure at $2.4 million in Q2 2026.
- Finished Goods for Q2 2026 came in at $2.4 million, up 125.65% year-over-year; the trailing twelve-month figure through Jun 2026 was $2.4 million (up 125.65% YoY), and the FY2025 annual result was $1.6 million, up 22.74% from the prior year.
- Finished Goods advanced to $2.4 million in Q2 2026, from $2.2 million in the prior quarter.
- Over five years, Finished Goods peaked at $2.4 million in Q2 2026 and troughed at $343000.0 in Q3 2022.
- A 5-year average of $1.2 million and a median of $1.2 million in 2023 frame the typical range for Finished Goods.
- The widest annual swing landed in 2022, when Finished Goods surged 198.05%; it then declined 20.45% in 2024.
- A 5-year view of Finished Goods shows it stood at $766000.0 in 2022, then grew by 29.37% to $991000.0 in 2023, then surged by 34.91% to $1.3 million in 2024, then grew by 22.74% to $1.6 million in 2025, then jumped by 49.06% to $2.4 million in 2026.
- Per Business Quant data, the three most recent Finished Goods figures were $2.4 million in Q2 2026, $2.2 million in Q1 2026, and $1.6 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.45 Mn |
| Mar 31, 2026 | 2.21 Mn |
| Dec 31, 2025 | 1.64 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 1.08 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.34 Mn |
| Sep 30, 2024 | 809,000.00 |
| Jun 30, 2024 | 1.22 Mn |
| Mar 31, 2024 | 1.33 Mn |
| Dec 31, 2023 | 991,000.00 |
| Sep 30, 2023 | 1.02 Mn |
| Jun 30, 2023 | 1.18 Mn |
| Mar 31, 2023 | 1.27 Mn |
| Dec 31, 2022 | 766,000.00 |
| Sep 30, 2022 | 343,000.00 |
| Jun 30, 2022 | 513,000.00 |
| Mar 31, 2022 | 459,000.00 |
| Dec 31, 2021 | 257,000.00 |
| Sep 30, 2021 | 289,000.00 |